Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Duvelisib - Secura Bio

Drug Profile

Duvelisib - Secura Bio

Alternative Names: ABBV-954; COPIKTRA; INK-1197; IPI-145; VS-0145; YHI-1702

Latest Information Update: 14 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intellikine
  • Developer AbbVie; CSPC Pharmaceutical Group; Dana-Farber Cancer Institute; Infinity Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Secura Bio; Verastem Oncology; Yakult Honsha
  • Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Antirheumatics; Isoquinolines; Purines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T-cell lymphoma; Chronic lymphocytic leukaemia; Peripheral T-cell lymphoma; Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia
  • Registered Follicular lymphoma
  • Phase III Non-Hodgkin's lymphoma
  • Phase II COVID 2019 infections; Haematological malignancies; Peripheral T-cell lymphoma; Squamous cell cancer
  • Phase I/II Malignant melanoma
  • Phase I Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Lymphoma; Solid tumours; T-cell lymphoma
  • Discontinued Allergic asthma; Rheumatoid arthritis

Most Recent Events

  • 22 Dec 2023 Secura Bio completes a phase II PRIMO trial in Peripheral T-cell lymphoma (Second-line therapy or greater) in Germany, Italy, United Kingdom, Japan, USA (PO) (NCT03372057) (EudraCT2019-001123-13)
  • 25 Jul 2023 Secura Bio completes phase II TEMPO trial for Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA, Czech Republic, Germany, Italy, South Korea, Poland, Russia and United Kingdom (NCT04038359)
  • 08 Jun 2023 Updated efficacy and adverse event data from the phase II PRIMO trial in Peripheral T-cell lymphoma presented at the 28th Congress of the European Haematology Association (EHA-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top